Dr. Xianglei Fu's Research Fellowship: Editing the Gene Behind CF, One Letter at a Time
November 17, 2026Share this:

Share this:

Cystic fibrosis (CF) is a genetic disease that affects many parts of the body, especially the lungs. It is caused by changes in a gene called CFTR, which can lead to thick, sticky mucus that makes it harder to breathe and can cause repeated lung infections.
Today, medicines called CFTR modulators help many people with CF, but they aren't a cure and they don't work for everyone.
With funding from Cystic Fibrosis Canada, Dr. Xianglei Fu is exploring a different approach: could we correct the genetic mutation that causes CF?
Through the Jennifer and Robert Sturgess Research Fellowship, Dr. Fu, a postdoctoral fellow at the University of Toronto, is studying gene editing — a technology that aims to precisely correct the genetic code to address the underlying cause of CF.
How could gene editing work in the lungs?
Current CFTR modulators help the CFTR protein work better. Gene editing aims to go a step earlier, repairing the genetic instructions that tell the body how to make that protein in the first place.
To explore whether this could one day work as a treatment, Dr. Fu needs to solve two big challenges: making the correct edit to the genetic instructions and getting the editing tools into the right cells in the lungs.
Getting a potential treatment into the lungs
Dr. Fu is developing tiny carriers, called lipid nanoparticles, that package these tools and carry them into the lungs when inhaled. Think of them as delivery vehicles transporting the gene-editing tools exactly where the researchers need them to go. CF can make that journey extremely difficult. When the lungs are filled with thick, sticky mucus, it can trap inhaled therapies before they ever reach the intended location. Dr. Fu is designing the carriers to move through that mucus and reach their target.
“The most transformative aspect is the administration route,” she says. “The lung is a unique organ because it's directly exposed to the outside environment.”
Inhaling the therapy allows it to reach the target cells in the lungs directly, without first travelling through the rest of the body.
These target cells, called airway basal cells, help repair and renew the lining of our airways. If the genetic change can be made in these longer-lasting cells, the hope is that new cells they produce could also carry that change.
"If we can correct mutations in these cells,” she explains, “the therapeutic benefit could last much longer.”
Making the change
So, what happens if the gene-editing tools reach those cells?
Our genes contain instructions that tell our bodies how to work. Those instructions are written using four chemical “letters”: A, C, G and T. Changes in these letters can affect how the CFTR protein works and cause CF.
Dr. Fu is studying base editing, a type of gene editing that can precisely change one of these letters.
As a proof of concept, she is focusing on a CF-causing genetic mutation called G551D. Dr. Fu’s team is studying whether changing one letter in the genetic code could allow the body to produce CFTR protein that works properly.
Dr. Fu’s research is still at an early stage. Over the next two years, she plans to refine the approach and test it to assess how well it works and how safe it is.
A research path shaped across three countries
Dr. Fu's research career has taken her from China to Belgium and now Canada.
"Moving to Canada and joining Dr. Li's lab has given me valuable opportunities to explore innovative ideas and be part of a collaborative community that connects research, patients, and clinical applications," she says.
"At this stage, the fellowship feels like meaningful validation that the therapeutic approach we propose could make a real difference for people living with cystic fibrosis."
"I truly appreciate the support from Cystic Fibrosis Canada," she adds. "I am especially honoured to be named the Jennifer and Robert Sturgess Fellow this year."
Hope for the future
For Dr. Fu, success is not only about scientific progress, but what that progress could mean for people living with CF and their families.
“If our work can contribute to a therapy that addresses the disease at its genetic root,” she says, “it could help people spend less time managing CF and more time simply living their lives and enjoying time with their families.”